Clearside Biomedical, Inc. (CLSD)

Market Cap	69.25M
Revenue (ttm)	1.66M
Net Income (ttm)	-34.35M
Shares Out	77.28M
EPS (ttm)	-0.47
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	129,218
Open	0.9000
Previous Close	0.8588
Day's Range	0.8608 - 0.9200
52-Week Range	0.7000 - 1.6500
Beta	2.11
Analysts	Strong Buy
Price Target	5.20 (+480.29%)
Earnings Date	May 14, 2025

About CLSD

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide injectable suspension for the treatment of macular edema associated with uveitis. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which has completed Phase 2 clinical trial to treat wet AMD. The company has a collaboration with bausch + lomb ireland limited, Arctic Vision (Hong Kong) ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 2, 2016
• Employees: 32
• Stock Exchange: NASDAQ
• Ticker Symbol: CLSD
• Website: https://clearsidebio.com

Financial Performance

In 2024, Clearside Biomedical's revenue was $1.66 million, a decrease of -79.77% compared to the previous year's $8.23 million. Losses were -$34.35 million, 5.75% more than in 2023.

Analyst Forecast

According to 5 analysts, the average rating for CLSD stock is "Strong Buy." The 12-month stock price forecast is $5.2, which is an increase of 480.29% from the latest price.

Price Target

$5.2

(480.29% upside)

Analyst Consensus: Strong Buy